美股
Lead report
Sanofi's Tzield Receives FDA Approval for Stage 3 Type 1 Diabetes Treatment, Boosting US Stock
Sanofi announced FDA approval of Tzield for stage 3 type 1 diabetes, filling an immunomodulatory therapy gap. Market response is positive, with analysts projecting peak sales of $2-3 billion, strengthening the company's metabolic disease pipeline.
